Active Subject Recruitment is ongoing for the following research studies and sponsors for Neurology:

  • Chicago Stroke Trials Consortium (CSTC) is a collaborative network of seven centers in the Chicago metropolitan area that aims at combining resources, diverse faculty with stroke expertise and access to multi-ethnic population of stroke patients from a combined geographic referral base encompassing almost 10 million people.   The CSTC aims to provide cutting edge stroke treatments to a diverse patient population, provide consolidation multi-disciplinary and multi-institutional expertise and leadership for Network trials, and ensure mentoring for the next generation of stroke investigators. (sponsor: NIH led by Northwestern University)
    Study PI: Dr. José Biller
  • Illinois Stroke Intervention Registry and Trials Network  (ISIRTN) The purpose of the study is to create a local research network of academic university medical centers in the Chicago, Illinois-wide area, practicing as comprehensive stroke centers with highly competent endovascular stroke intervention practices by establishing a multicenter, prospective clinical and imaging data registry of stroke intervention patients, centralized across this academic network
    Study PI Neurologist: Dr. José' Biller, Neurointerventionalist:  Dr. Asterios Tsimpas
  • Platelet-Oriented Inhibition in New TIA or Minor Ischemic Stroke (POINT) (sponsor: NIH and University of San Francisco)
    Study PI:  Dr. Michael Schneck
    POINT is a multicenter clinical trial to determine if the addition of clopidogrel to aspirin in stroke patients decreases the risk of major ischemic vascular events compared to aspirin alone. To view more regarding this study click the following link:
  • Minimally Invasive Surgery Plus rt-PA for Intracerebral Hemorrhage Evacuation (MISTIE III) (sponsor: Johns Hopkins and NIH)
    Study PI: 
    Dr. William Ashley
    MISTIE III is an international multicenter clinical trial to confirm the safety and log-term efficacy of thrombolysis in the treatment of intracerebral hemorrhage (ICH).  To view more regarding this study click the following link:
  • Study of Deferoxamine Mesylate in Intracerebral Hemorrhage (iDEF) (sponsor:  Beth Israel Deaconess Medical Center  and NIH)
    Study PI:  Dr. Michael Schneck
    iDEF is a multi-center clinical trial to determine whether treatment with Deferoxamine Mesylate (an iron chelator) is sufficient to improve outcomes for treatment of intracerebral hemorrhage before pursuing a larger clinical trial to examine effectiveness.  To view more information regarding this study click the following link: 
  • Safety study in Patients with Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies (PASSAGE) (sponsor:  Novartis)
    Study PI:  Dr. Matthew McCoyd
    PASSAGE is a world-wide prospective study in patients with relapsing forms of Multiple Sclerosis, either newly treated with fingolimod or receiving another disease-modifying therapy, is to explore the incidence of selected safety-related outcomes and to further monitor the overall safety profile of fingolimod under conditions of routine medical practice.

Please contact the Department of Neurology Research Coordinator, Tara Bernier-Lynch, RN at for more information.